Mini-dose glucagon may prevent exercise-associated hypoglycemia in patients with type 1 diabetes

Written By :  Dr Kartikeya Kohli
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-01-27 05:30 GMT   |   Update On 2023-01-27 07:06 GMT

Canada: Mini-dose glucagon with or without a 50% reduction in CSII (continuous subcutaneous insulin infusion) basal delivery rate may decrease exercise-associated hypoglycemia (EAH) incidence in patients with type 1 diabetes, says a recent study. The study's findings appeared in the journal Diabetes Care on January 23 2023.

Glucagon is the standard of care for hypoglycaemia treatment. Ronnie Aronson from LMC Diabetes & Endocrinology in Toronto, Ontario, Canada, and colleagues aimed to determine the effect of ready-to-use, mini-dose glucagon on the incidence of exercise-associated hypoglycemia in adults with type 1 diabetes.

Advertisement

The patients initially participated in the in-clinic training phase for which they were randomly allocated to 150 µg glucagon labelled as treatment arm A or placebo labelled as arm B subcutaneously in a crossover design immediately before exercise, plus a 50% reduction in continuous SC insulin infusion basal delivery rate. Then the completers were randomly assigned in the outpatient investigational phase of 12 weeks: arm A, B, or open-label C, 150 µg glucagon alone.

The patients, in real-world settings, performed their usual aerobic exercise with moderate to high intensity for 30 to 75 min. Data analysis was done for the level 1 hypoglycemia incidence based on self-monitoring blood glucose and several exploratory and secondary endpoints.

The authors reported the following findings:

  • Forty-five continued to the outpatient phase out of 48 participants who completed the training phase.
  • Level 1 hypoglycemia incidence for all exercise sessions in the outpatient phase (n = 795) was lower in both glucagon arms (A, 12%; C, 16%) versus the placebo arm (B, 39%).
  • Among treatment arms, times in range, below range, and above range from 0 to 300 min did not remarkably differ.
  • With glucagon use, consumed grams of exercise carbohydrates were lower than placebo but did not reach statistical significance.
  • Adverse events were comparable among treatment arms.

"In adults with type 1 diabetes, mini-dose glucagon with or without a 50% reduction in CSII basal delivery rate may help to decrease the incidence of exercise-associated hypoglycemia," the researchers concluded.

Reference:

Ronnie Aronson, Michael C. Riddell, Valentina Conoscenti, M. Khaled Junaidi; Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2023; dc221145. https://doi.org/10.2337/dc22-1145

Tags:    
Article Source : Diabetes Care

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News